The aim of this study was to evaluate the expression of leptin and its receptor in histological sections of prostate tumors, and their association with prognostic factors.
Introduction
Leptin is a hormone responsible for regulating body fat.
It is secreted by adipocytes, and its serum level varies with body weight and physical activity. Like other hormones, leptin needs to bind a receptor to exert its effects 1, 2 . Therefore, not only the amount of leptin but also the number of leptin receptors on a target cell is important in determining its activity.
In vitro studies have shown that leptin is a mitogenic factor in several malignancies, including endothelial, breast, colon, prostate, and esophageal cancers 3, 4 . Leptin also stimulates the growth and migration of neoplastic cells in vitro and increases the proliferation of prostate cancer (PCa) cells via the suppression of apoptosis, thus mediating more aggressive biological behavior 3, 4 .
Leptin only stimulates cell proliferation in some androgen-independent PCa-derived cell lines, but not in cells derived from androgen-dependent tumors, despite both cell types expressing functional leptin receptor isoforms 5 . Leptin has been
shown to have a role in the development of PCa via testosterone and obesity-related factors and influences the cellular differentiation and progression of this malignancy 6, 7 .
Analysis of leptin expression in PCa and benign prostatic hyperplasia (BPH) has shown that it is more abundant in the former.
Leptin expression is greater still in metastatic and locally advanced prostate tumors compared to localized tumors. Therefore, it has been suggested that the increased expression of leptin is related to the progression and degree of malignancy of this disease 8, 9 .
Different methods have been used to determine the prognosis of PCa. These include histopathological classification through the scoring system devised by Gleason, which is widely used, as it correlates with disease progression 10, 11 . The Gleason's score correlates with the levels of prostate specific antigen (PSA), clinical and pathological staging of the disease, frequency of corpuscle apoptosis, over expression of p53, the incidence of lymph node and bone metastases and response to therapy 12, 13 .
Although the Gleason score is the best method for determining a prognosis in PCa, differences in scores may occur when different pathologists analyze the same sample.
In addition to Gleason score, the prognosis of PCa is also related to a number of other factors, including pathological staging criteria such as capsular penetration, positive surgical margin, the involvement of urethral and vesical margins, seminal vesicle invasion, and lymph node involvement [13] [14] [15] .
This study was designed to evaluate, by quantitative Samples embedded in paraffin (donor block) were selected and labeled in blue to mark tumor fields and red to mark BPH fields.
From each selected area of the donor block, a core was collected by direct puncture of the marked area with 1-mm diameter needle. These cores were included in a new block (receiver block). Four blocks of tissue microarray (TMA) with a total of 1,064 specimens (tumor and BPH532, 532) were prepared.
Histological sections were cut from these four TMAs.
The expressions of leptin and its receptor were assayed Additionally, no significant difference was found between the expression of leptin in tumors with different Gleason scores: low (≤6), intermediate (7), and high (≥8).
There was also no significant difference in the expression of leptin with respect to the different prognostic factors analyzed. However, the expression of leptin receptor was reduced by 11.3%, 4.6%, and 6.4% in tumors that exhibited urethral margin involvement, a positive surgical margin, and seminal vesicle invasion, respectively, in comparison to those that do not exhibited these factors (Figure 3) . 
Discussion
Patients with prostate cancer have elevated serum levels of leptin 16 , and this is correlated with tumor volume, histological classification, biochemical recurrence, metastasis, and disease progression, as well as an increase in mortality 6 . There is also a strong correlation between serum leptin levels and PSA 16, 17 .
With respect to prostate tissue, leptin is expressed more strongly in tumors than in hyperplasic tissues; the expression of leptin was also elevated in locally advanced and metastatic tumors compared with localized tumors 8 . Therefore, increased leptin expression was predicted to be associated with progression and malignancy of disease.
However, we found no difference between the expression of leptin or its receptor between tumor and non-tumor tissue. This may relate to the methodology used for the quantification of leptin.
In our study, we performed a computational analysis rather than an analysis based on a subjective method that depends on the observer's interpretation of immunolabeling intensity as being either strong or weak 8 . Our results confirm this assertion, with a significant difference between the subjective analysis of the two observers quantifying leptin and its receptor. Subjective methods for the analysis of morphological changes are highly influenced by the observer and thus, often difficult to reproduce. Quantitative computational methods should be used instead of subjective methods, as the latter may show a greater variation 18 .
We also reviewed pathological data, such as perineural and seminal vesicles invasion, vascular embolization, bilateral involvement of the lobes, vesical and urethral margin involvement, and positive surgical margin. In addition to the Gleason score, each of these factors influence prognosis to some extent 19 . It has been suggested that leptin expression is also a potential prognostic factor in PCa, although we found no association between leptin expression in tumors and any of these other prognostic factors.
However, we found that the expression of leptin receptor was significantly lower in tumors exhibiting a number of prognostic factors, including urethral margin involvement, surgical margin involvement, and seminal vesicles involvement.
There was also a negative correlation between the sum of these study that considers more clinical data and that which involves a longer follow-up period is needed to corroborate our findings.
Conclusions
Leptin receptor is a possible prognostic factor in PCa, as its expression is lower in the presence of a surgical margin involvement, urethral margin involvement, and seminal vesicle invasion, and that there is a negative correlation between the sum of key prognostic factors and leptin receptor expression.. However, we found that the expression of leptin itself on tumor histological sections had no apparent prognostic significance.
